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Summary 
Recombinant streptococcal pyrogenic exotoxin C  (SPE-C) is a potent superantigen that stim- 
ulates VJ32-bearing human T  cells,  but is inactive in mice. SPE-C binds with high affinity to 
both human HLA-DR and murine I-E molecules, but not to routine I-A molecules in a zinc- 
dependent fashion.  Competition binding studies with other recombinant toxins revealed that 
SPE-C lacks the generic low affinity major histocompatibility complex (MHC) class II (x-chain 
binding site common to all other bacterial superantigens. Despite this, SPE-C cross-links MHC 
class II to induce  homotypic aggregation of class  II-bearing B  cells.  Nondenaturing  sodium 
dodecyl sulfate electrophoresis and size exclusion chromatography revealed that both wild-type 
and recombinant SPE-C exist in a stable dimer at neutral or alkaline pH. These data support a 
recent crystal structure of SPE-C and reveal yet another mechanism by which bacterial super- 
antigens ligate and cross-link MHC class II. 
B 
acterial superantigens (SAgs) 1 produced by Staphylococ- 
cus aureus and Streptococcus pyogenes simultaneously bind 
to MHC class II antigens and T  cell receptor molecules via 
the V[3 domain and stimulate large numbers of T  cells (1-3). 
SAgs stimulate high systemic levels of the proinflammatory 
cytokines TNF-ot and IL-lJ3 and the T  cell mediators IL-2 
and  INF-'y that  cause hypertension,  fever, and shock.  All 
SAgs require  initial  presentation  by MHC  class  II mole- 
cules for maximal activity (4-7), but the role of the MHC 
class II molecule appears to differ depending  on the  SAg. 
Crystal structures are now available for staphylococcal en- 
terotoxin (SE)A  (8),  SEB  (9),  SEC2  (10),  and toxic shock 
syndrome toxin (TSST; 11),  and although there are signifi- 
cant differences in surface features, each molecule conforms 
to the same overall folding pattern, with a small N-terminal 
B-barrel  globular  domain  and  a  larger  COOH-terminal 
globular domain of the B-grasp motif. Despite conservation 
of three-dimensional structure, individual staphylococcal and 
streptococcal SAgs have developed different ways of bind- 
ing to  MHC  class  II. For example,  SEB  and toxic shock 
syndrome toxin TSST-1  both bind to the invariant MHC 
class  II (x  chain,  but  SEB  binds  out  to  the  side  of the  (x 
chain leaving the top of the class II molecule exposed (12), 
whereas TSST binds over the top of the class II (x chain and 
obscures the (x chain ot helix, the peptide, and some of the 
1Abbreviations used in thispaper: GST, glutathione S transferase; m, messen- 
ger; SAg, superantigen; SE, staphylococcal  enterotoxin; SPE, streptococ- 
cal pyrogenic  exotoxin; TSST, toxic shock syndrome  toxin. 
[3 chain (x helix (13). This implies that TCRs, when ligated 
by TSST,  do  not  contact  the  MHC  class  II molecule to 
which TSST is bound. SEB, on the other hand, appears to 
rely heavily on continued interaction between TCRs and 
MHC class II to stabilize a trimeric complex between SEB, 
MHC class II, and TCR (14-16). 
Some SAgs, such as SEA, have an additional binding site 
for the polymorphic J3 chain of MHC class II (17-19) that 
is  100  times stronger than (x-chain binding.  This interac- 
tion  results  from a  tetrameric  zinc  coordination  complex 
between  H187,  H225,  and D227  of SEA  and  the  highly 
conserved H81 of the MHC class II [3 chain (17),  and pro- 
vides SEA with the ability to cooperatively bind and stabi- 
lize  a  second  SEA  molecule  to  the  low  affinity  class  II 
c~-chain site, promoting cross-linking of MHC class II mol- 
ecules on the surface of the APC (17-19).  Cross-linking of 
MHC  class II is an important component of SEA activity 
(18,  20),  although the exact mechanism by which this en- 
hances SAg stimulation is not yet known. Experimental ev- 
idence indicates that the low aflfinity o~-chain  interaction is 
more important to TCR ligation than MHC class II bind- 
ing because mutations in  this  site  affect T  cell  activation 
without significantly altering class II binding, whereas mu- 
tations in the J3-chain site destroy all J3- and (x-chain bind- 
ing, and subsequent T  cell activation (18,  19). 
Despite  their  role  in  human  disease,  the  streptococcal 
toxins have not been as well studied as the staphylococcal 
toxins. There are three known streptococcal superantigens, 
streptococcal pyrogenic exotoxin (SPE)-A, SPE-C (21), and 
SSA (22).  SPE-A and SSA are most similar in sequence to 
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member of the  SAg family, and is least homologous with 
TSST. Nevertheless, there is sufficient sequence homology 
among all of the staphylococcal and streptococcal toxins to 
suggest that  they have  evolved from a  common ancestral 
gene and are likely to fold in a similar manner. 
This  study  has  examined SPE-C  in  detail  and  reveals 
unique features that distinguish it from other superantigens. 
Like TSST, SPE-C is a powerful in vitro activator of hu- 
man VI32-bearing T  cells with a potency approaching that 
of SEA.  However,  recombinant SPE-C is totally inactive 
against routine T  cells.  Evidence is presented that  shows 
that SPE-C is a dimer molecule that no longer uses the ge- 
netic o~-chain binding site, but instead binds only to the 13 
chain of MHC class II by a zinc-mediated mechanism sim- 
ilar to  SEA.  The conclusions made from these  functional 
data are supported by the recently resolved crystal structure 
of SPE-C (23). 
Materials and Methods 
Toxin Purification.  All toxins were expressed from the pGEX 
vector in Escherichia coli as glutathione S transferase (GST) fusion 
proteins and purified by glutathione chromatography as previ- 
ously described  (24). Mature toxins were cleaved from GST by 
trypsin digestion and purified by two rounds of cation exchange 
chromatography. The first round using carboxymethyl sepharose 
and the  second on a  POROS  HS  (Perceptive  Systems,  Cam- 
bridge,  MA)  HPLC column. All toxins were resistant to trypsin 
digestion except SEB which has a single cleavage site in the disul- 
phide loop region. This does not affect SEB activity. 
Toxin Proliferation Assays.  Human peripheral blood lympho- 
cytes were purified by Ficoll-Hypaque and incubated for 3 d at 
106  cells/m] in duplicate in 96-well microtiter plates in media 
containing varying dilutions  of recombinant toxins.  0.1  p-Ci 
[3H]thymidine was added to each well, and cells were incubated a 
further 24 h. Plates were harvested and counted on a scintillation 
counter. 
Radiolabeling and Cell-binding Experiments.  5  p-g  of  purified 
toxin was radioiodinated by the chloramine T  method to a spe- 
cific activity of "~50-100 p.Ci/p~g. Labeled  toxin was separated 
from free  iodine on a  1 ml Sephadex G25  (Pharmacia,  Piscat- 
away,  NJ)  column and stored at  1 p-g/ml in 50% glycerol-l% 
hemaglobin phosphate buffered saline. LG-2 cells are a human B 
lymphoblastoid cell line homozygous HLA-DR1. Cells were har- 
vested in log phase,  washed  in RPMI/10% fetal calf serum, and 
suspended at 107/ml of the same medium. For duplicate binding 
studies using either SEA, TSST, or SPE-C, the 125I-tracer toxin 
was used at 2 ng/tnl with the addition of 0.01-100 p-g of unla- 
beled toxin. 106 cells (100 p.1) were added and incubated for 1 h 
at 37°C.  Cells were washed  three times  with ice-cold medium 
and centrifuged pellets  were counted in a gamma counter. For 
SEB inhibition studies,  1 p-g/m]  of ~25I-SEB was used as tracer 
due to the much lower affinity that SEB binds to LG-2 cells with, 
and samples were incubated for 4 h  at 37°C before washing and 
counting. For binding studies to mouse B  cells, single cell sus- 
pensions ofsplenocytes were pretreated at 5 ×  106/ml for 4 d in 
vitro with 20 p-g/m] lipopolysacharride  (Sigma Chemical Co., St. 
Louis,  MO) in 10% FCS-DMEM to  generate B  cell blasts that 
were harvested  and used for cell binding at  107 cells/tube. Cells 
were incubated for 1 h at 37°C, and then washed  three times in 
ice-cold medium before gamma counting. 
Fluorescence Labeling of SEB.  1 mg (1  mg/ml) SEB in 0.1  M 
sodium carbonate, pH 8.5, was incubated with 20 p-1 of 5 mg/ml 
fluorescein isothiocyanate  in DMSO (Sigma Chemical Co.) over- 
night in the dark at room temperature. Fluoresceinated SEB was 
separated  from free FITC on a 1-ml G25 column and stored  at 
4°C with 0.02% NAN3. LG-2 cells (6 ×  105 cells) were incubated 
for 2 h at 37°C with shaking with 1 Ixg/ml FITC SEB and a 10- 
fold serial dilution of unlabeled toxin starting at 0.1 mg/ml. After 
incubation, cells were washed with 2  ×  0.5 ml ice-cold PBS and 
examined immediately on a FACSCAN  ® (Becton Dickinson, San 
Jose,  CA). 
TCR  V~ Analysis.  These were performed as previously de- 
scribed using the reverse dot-blot procedure (24). In brief, human 
peripheral blood lymphocytes were incubated at  10S/ml with 1 
ng/ml of recombinant toxins for  3  d.  The  cultures  were  ex- 
panded twofold with medium containing 20 ng/ml IL-2.  Cells 
were harvested  at 4 d  and RNA made by standard  procedures 
(25). TCR [3-chain messenger was reverse transcribed using a set 
of primers specific for a conserved region in all 13-chain genes. 
Amplification ofa 500-bp V[3 probe was accomplished  by an an- 
chor primer to the 5' end of the ]3-chain primers plus a single CI3 
region primer. This probe was radiolabeled and reverse blotted to 
filters containing individual [3-chain genes.  Relative changes  in 
individual ~3-chain mRNA were compared to unactivated PBL. 
Anti-TCR mAb FACS  ~ Staining.  Activated T  cells were in- 
cubated for  1 h  on ice with 25 ml of anti-TCR BV2  (MPB2/ 
Cll;  a  gift  from A.W.  Boylston,  Universtiy of Leeds,  Leeds, 
UK), anti-BV551 (LC4; a gift from R. Levy, Stanford University 
Medical School,  Stanford, CA), anti-BV5S3 (42/1C1; a gift from 
A.W.  Boylston, Universtiy of Leeds,  Leeds,  UK),  anti-BV8.1 
(C305;  a gift from A. Weiss, University of California, San Fran- 
cisco, CA), and anti-BV12S  ($511; a gift from D. Posnett,  Comell 
University Medical College,  NY). Washed cells were then incu- 
bated with 1 ml FITC goat anti-mouse (Becton Dickinson) and 
incubated on ice for a further 30 rain. After washing, cells were 
analyzed on a FACSCAN  ®. 
Zinc Blots.  Recombinant toxins (10  p-g) were  incubated in 
triplicate with 10 p~M EDTA followed by 100 p-M 6sznc1 (New 
England Nuclear, Boston, MA) in 20 mM Tris, pH 8.0,  10 mM 
MgC12, 0.15 M NaC1 made zinc free by addition of chelex resin 
(Sigma Chemical Co.) as previously described  (17). Samples were 
then dot blotted to nitrocellulose filters using a 96-well dot-blot 
apparatus.  Filters were washed  briefly three times with zinc-free 
buffer,  and  then  autoradiographed.  Spots  were  cut  out  and 
counted  on  gamma  counter  (Packard Instrs., Meriden CT)  to 
quantify 6SZn  bound to each toxin. 
Nondenaturing SDS Electrophoresis.  Toxin samples were incu- 
bated in standard Laemmli reducing sample buffer (containing 1% 
SDS and 10 mM dithiothreitol), and then resolved as normal of a 
12.5% acrylamide  gel.  For denaturing conditions, samples were 
heated to  100°C  for 2  rain before loading. To prevent dimers 
from dissociating during running, the power was maintained be- 
low 2 W  (20 mA and 100 V). Some reduced samples were treated 
with 20 mM iodoacetic acid, pH 7.0, before loading. EDTA was 
added to some samples at 10 mM. 
LG-2 Cell Aggregation Assay.  Healthy LG-2 were washed  in 
RPMI-10% FCS, vigorously resuspended at 5 ×  105 cells/m] in 
RPMI-10% FCS and aliquoted as a single-cell suspension to a 
96-well flat-bottom plate in a final volume of 100 p-1. Cells in du- 
plicate wells were stimulated by the addition of toxin to ,'J37 nM 
(l.0 p.g/ml). Aggregation was scored  at various time points after 
376  SPE-C Structure and Function Table 1.  Relative Potency of Recombinant  SA on Human and Mouse T  Cells 
Prohferation potential P50~ 
BALB/c  SJL  B10.M  C57B1/6  C3H  Human PBL 
pg /ml 
SEA  40  0.1  80  6  20  0.01 
SEB  4  900  200  10,000  300  0.04 
SPEC-C  >100,000  > 100,000  > 100,000  > 100,000  > 100,000  0.005 
TSST  2  20  ND  0.6  20  0.03 
Values reflect the concentration  of recombinant  toxin required to produce 50% maximal proliferation. There was no detectable prohferation for 
SPE-C at the highest concentration tested on murine splenocytes. 
incubation at 37°C as the percentage of LG-2 cells in aggregates, 
and was determined by light microscopy. 
Western  Blotting  of S.  pyogenes  Strain  2035-derived  SPE-C. 
S. pyogenes strain 2035 was grown under anaerobic conditions in 
brain heart fusion medium at 37°C for 24 h without shaking. Su- 
pernatant proteins were  concentrated by sequential  (NH4)2SO 4 
precipitations, with  cuts of <40%,  40-60%,  60--80%,  and 80% 
saturation, and resuspended in 50  mM Tris-1  mM EDTA, pH 
7.4, at N500--1,000 times their original concentration, tkecombi- 
nant  SPE-C  or  10  I~1  of the  60-80%  (NHa)zSO4-precipitable 
fraction of 2035  supematant were combined with an equal vol- 
ume  of nonreducing  2%  SDS  sample buffer and  separated by 
0.1%  SDS-12% PAGE. Denatured samples were heated (95°C) 
for  2  rain  before  analysis.  Fractions were  dialyzed extensively 
against 25 mM Tris-50 mM NaCI-1 mM EDTA, pH 7.4, to re- 
move salt. After separation by SDS-PAGE, proteins were trans- 
ferred to a nitrocellulose filter (Hybond-C; Amersham Corp., Ar- 
lington Heights, IL) in an electroblotting apparatus using Towbin 
buffer lacking SDS (25 mM Tris.HC1, pH 8.5-150 mM glycine- 
10% methanol). The filter was blocked in PBS-0.05% Tween-5% 
nonfat dried milk powder-0.1% normal rabbit serum and stained 
with 1:6,000 peroxidase-labeled af~fity-purified rabbit anti-SPE-C 
immunoglobulin. The peroxidase conjugate was detected on ra- 
diographic film by chemiluminescence (ECL; Amersham Corp.) 
according to the manufacturer's instructions. 
Size Exclusion  Chromatography.  Recombinant SPE-C  (2 mg/ 
mi) was dialyzed at 4°C overnight in 20 mM BisTris-Tris, pH 6.0 
or 9.0.  20 Ixl samples were diluted into  100  p~l 50 mM BisTris, 
pH 6.0,  7.0,  8.0,  or 9.0/0.1  M  NaC1 and incubated for  1 h  at 
room temperature before separation at 1 ml/min (+0.05 ml/min) 
on a Superose12 (Pharmacia) high resolution HPLC column at- 
tached to  a  Biocad Sprint  (Perceptive Systems)  preequilibrated 
with  the  respective  incubation  buffer.  Trace  chromatograms 
monitoring Abs280~  ,, pH, and conductivity were all recorded di- 
rectly and subsequently analyzed for retention times, peak inte- 
gration, and peak assignment using the on-line Biocad software. 
Traces  were  grouped and  printed using the  stacked trace  mode 
which automatically aligns each trace to the injection point. 
Results 
All toxins were  expressed in E.  coli as GST fusion pro- 
teins and purified by glutathione agarose affinity chroma- 
tography, cleaved with trypsin, and purified by HPLC to a 
point of apparent homogeneity by SDS-PAGE gel analysis. 
To  ensure  native conformation after expression in E.  coli, 
each  recombinant  toxin was  tested for its potency in  the 
standard  3-d  [3H]thymidine  assay.  All,  including  SPE-C, 
were active at concentrations <  1 pg/ml on human T  cells 
(Table 1). The most potent of the recombinant toxins was 
SPE-C, which gave a half-maximal response of 5 fg/ml and 
was  still active  at  <0.1  fg/ml.  In  contrast,  SPE-C  com- 
pletely lacked proliferative activity for mouse T  cells in all 
strains tested. No activity was observed above background 
in any mouse  strain,  even  at the  highest concentration  of 
SPE-C  tested  (100  tzg/ml).  By  comparison,  all other re- 
combinant toxins were active on murine T  cells at <  1 ng/ 
ml (except for SEB on C57B1/6).  The prohferative activity 
varied greatly between  strains  and  toxins  (Table  1).  The 
half-maximal activity of SEB on BALB/c T  cells was 4 pg/ 
ml,  but  10,000  pg/ml  for  C57B1/6  mice,  representing  a 
2,500-fold  difference between  the  two  strains.  The  most 
consistently  potent  toxin  on  mouse  T  cells  was  TSST, 
which  varied in  its half-maximal activity from  0.6  pg/ml 
for C57B1/6 mice to 20 pg/ml for C3H mice. 
Amino acid sequence alignment of SEA and SPE-C re- 
vealed that SPE-C shared two out of the three zinc coordi- 
nating residues present in SEA. Residues H201  and D203 
in  SPE-C  are  analogous  to  H225  and  D227  in  SEA that 
form the essential bidentate component found in all solvent 
exposed zinc sites (8, 26). This suggested that SPE-C might 
bind  zinc  in  the  same  way  as  SEA.  Identification of the 
third hgand  was  not  obvious from  direct sequence  align- 
ment because the  corresponding residues to  SEA-H187  is 
G161,  which is unlikely to act as a  zinc hgand.  However, 
three other residues in close proximity to G161  could po- 
tentially serve  as  zinc ligands.  These  are E159,  D164,  or 
H167. 
Recombinant SPE-C was tested for its ability to bind ra- 
dioactive 65Zn in a  zinc dot-blot assay alongside recombi- 
nant  SEA,  SEE,  SEB,  and  SPE-A  (Fig.  1).  SPE-C  bound 
6SZn 100 times greater than background and 50-fold higher 
than either SEB or SPE-A (two toxins that do not require 
Zn  2+  for  superantigen function).  SEA bound  the  highest 
levels of 6SZn in this assay, whereas both  SPE-C and SEE 
bound approximately half this level. Given that bound 65Zn 
is  determined  at  nonequilibrium  conditions,  these  differ- 
377  Li et al. Figure  1.  6SZn binding  to 
SPE-C.  Recombinant  toxins 
were  incubated  with  100  IJ.M 
65Zn and blotted in triplicate to 
nitrocellulose. After washing, the 
strips were autoradiographed and 
the individual dots counted. 
ences reflect a combination of both the equilibrium condi- 
tions,  these  differences reflect a  combination  of both  the 
equilibrium affinity and the off-rate of zinc for the different 
toxin binding sites. 
The importance of zinc to SPE-C activity was examined 
with  direct binding  of 1251 SPE-C  to  human  and  mouse 
cells expressing MHC  class II (Fig. 2).  SPE-C bound with 
high affinity to human LG-2 cells (which are homozygous 
HLA-DP,.1), but binding was  completely abolished in the 
presence  of 10  p.M EDTA  (Fig. 2  A). Equivalent binding 
was seen in MHC  class II mice expressed on LPS-activated 
mouse spleen cells expressing both I-A and I-E (BALB/c I-E  b, 
C3H/HeJ  I-E').  Strains  such  as  C57B1/6,  B10M/Sn,  and 
SJL/J  B-cell blasts that lack expression  of the  I-E[3  chain 
bound 125I-SPE-C poorly (Fig. 2  B) demonstrating that the 
primary target for SPE-C was the I-E molecule. Maximum 
binding of SPE-C to both human and mouse cells was re- 
stored by a  10 p,M excess of zinc over the EDTA. 
Competition binding experiments between  SPE-C  and 
other  toxins were  performed in  an  attempt  to  determine 
the orientation of SPE-C  on MHC  class II. The results of 
these binding experiments  are  shown  in  Fig.  3.  SEA was 
the only toxin to inhibit 125I-SPE-C binding to LG-2 cells, 
and  was  only  slightly less  competitive  than  SPE-C  itself 
(Fig.  3  A). Neither TSST  nor SEB  inhibited 125[-SPE-C, 
even  in  10,000-fold  molar  excess.  Both  SEB  and  TSST 
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Figure  2.  SPE-C  binding  to 
human  and murine  MHC  class 
II.  Radioiodinated  SPE-C  was 
incubated  with  (A)  106  LG-2 
cells  or  (B)  106  LPS-activated 
mouse splenocytes with increas- 
ing amounts of unlabeled SPE-C 
for  1 h  at  37°C, and  then  the 
cells were washed and counted. 
(A) [], Incubations in the media; 
O, media plus 10 mM EDTA; or 
O,  media  plus  10  mM  EDTA 
and  20  mM  ZnC12.  (B)  [], 
B10M;  0,  SJL/J; O,  BALB/c; 
&, C3H; ©, C57. 
bind exclusively to the MHC  class II ot chain  (12,  13).  In 
the reciprocal experiment, only SEA and SPE-C prevented 
12sI-SEA binding (Fig. 3  B). Neither SEB nor TSST inhib- 
ited. Although SEA and SPE-C appeared to bind to MHC 
class II in a similar fashion, competition experiments using 
12sI-SEB revealed important differences (Fig. 3  C). Even at 
the  highest  concentration  tested  (10  p,g/ml),  SPE-C  did 
not  inhibit  12sI-SEB  binding to  LG-2  cells, whereas  SEA 
remained an effective competitor, almost as efficient as SEB 
itself.  The  same  experiment was  performed  using  FITC- 
labeled SEB  (Fig.  3  D)  with  identical results,  confirming 
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Figure  3.  Competition  bind- 
ing studies. [/], SPE-C; 0, SEA; 
O,  SEB; &,  TSST.  (A)  125I- 
SPE-C was incubated at 2 ng/ml 
with 106 LG-2 cells in the pres- 
ence of  increasing concentrations 
of unlabeled SPE-C, SEA, SEB, 
or TSST.  Cells were  incubated 
in  duplicate for  1  h,  and  then 
washed and counted in a gamma 
counter.  (B)  Same as above ex- 
cept 125I-SEA  was the tracer. (C) 
Same as above except that lzsI- 
SEB was the tracer. (D) Fluores- 
ceinated SEB (1 mg/ml) was in- 
cubated  for  2  h  at  37°C with 
LG-2  cells, and  then  washed 
briefly and analyzed by FACS  ® 
analysis. (E)  Same as above ex- 
cept  I~SI-TSST  was used as the 
tracer. 
378  SPE-C Structure and Function that SPE-C does not share with SEA the ability to prevent 
SEB  binding  and  thus  is  unlikely  to  bind  directly  to  the 
MHC  class  II  ot  chain.  The  ability  of SPE-C  to  inhibit 
TSST  binding  was  also  tested  (Fig.  3  E).  SPE-C  was  a 
strong inhibitor of 125I-TSST binding,  a result contrary to 
the  reverse  experiment  (Fig.  3 A)  that showed that TSST 
did not prevent SPE-C binding. 
The human TCR  V[3 specificity of recombinant SPE-C 
was determined by reverse PCR  dot-blot analysis (24) and 
the relative V[3 enrichment compared with that induced by 
SPE-A or  Con  A.  The  results  are  presented  in  Table  2. 
SPE-C  almost  exclusively targeted  VI32-bearing cells,  en- 
riching this  particular  V[3  mRNA  over 30-fold  (2-60%). 
The only other V[3s displaying significant enrichment over 
the  Con A-activated control sample were V[34.1  (2-fold), 
V1312.5  (9-fold),  and  V[315  (1.6-fold),  which  increased 
from 0.2 to 1.7% (an 8-fold increase).  The sum total of all 
V~s stimulated by SPE-C was 94.4%, suggesting that all the 
VI3 species targeted were accounted for in the probe panel. 
This was in contrast to SPE-A where the panel of V[3 probes 
represented only 22.7% of the total enriched [3-chain cDNA. 
Presumably,  other V~s absent from the probe panel were 
the major target of SPE-A action. All summed V[3s in the 
Table 2.  V~ Specificity of SPE-C on Human T  Cells 
Percent V[3 enrichment 
Resting  Con A  SPE-A  SPE-C 
VI3  PCR  mAb  PCR  mAb  PCR  mAb  PCR  mAb 
1.1  0.0  0.0  0.0  0.5 
2.1  2.3  3  2.8  2  1.3  <1  59.6  19 
3.2  6.0  15.7  10.4  18.8 
4.1  5.8  3.3  1.4  6.8 
5.1  4.2  2  3.3  1.7  1.1  <1  1.4  3 
5.3  2.9  1.5  6.3  1.7  0.9  <1  1.0  <1 
6.3  0.7  0.9  0.3  0.6 
6.4  0.6  0.9  0.3  0.8 
6.9  1.2  2.4  0.0  1.0 
7.4  1.1  4.1  0.4  0.0 
8.1  0.5  <1  3.0  2  0.4  <1  0.2  <1 
9.l  0.0  0.4  0.0  0.1 
12.5  0.3  1  0.2  <1  1.5  <1  1.7  1.5 
15.1  0.4  0.8  4.6  1.2 
23.1  1.1  0.3  0.2  0.7 
Totd  27.1%  44.6%  22.7%  94.4% 
Human PBL were incubated with 1 ng/ml of  recombinant toxins for 5 d. 
Relative enrichment of VI3 cDNAs was analyzed by PCR reverse dot 
blot (24). Cells were also stained with anti-V]3 mAbs at 5 d, after stimu- 
lation. PCR figures represent percentage of V[3 with respect to total 
C[3. Antibody staining represents percent of total CD3 staining cells. 
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Figure  4.  SPE-C and SEA induce homotypic aggregation in  LG-2 
cells. Freshly split LG-2 cells were incubated with 1 I~g/ml of recombi- 
nant toxin in 24-well culture plates and monitored for 24 h. Percent ag- 
gregation was determined by counting the number of cells not bound to 
an aggregated clump. 
Con A-activated  sample  amounted  to  only 44.6%  of the 
total  [3-chain cDNA, indicating  that  the  V[3 panel  repre- 
sented  about half of the  total pool of transcribed  TCR  [3 
chains.  The  PCR  data  were  compared  to  surface  TCR 
staining using a limited panel of anti-human TCR mAbs to 
V[32, 5.1, 5.3, 8.1, and 12. The results were mainly consis- 
tent,  although the crucial V[3 staining of SPE-C-activated 
cells reflected a more modest increase in V[32-bearing cells 
from 2% in Con A-activated cells  to  19% for SPE-C (10- 
fold increase)  after  4  d  of stimulation.  The  difference  be- 
tween PCR data and surface staining may simply reflect the 
more rapid and greater increase in intracellular TCR  [3-chain 
mRNA  levels in activated T  cells,  compared to the much 
slower increase in cell number after activation. 
SEA and anti-MHC  class II mAbs such as LB3.1  rapidly 
induce  homotypic aggregation of LG-2 cells.  In addition, 
both these  MHC  class  II ligands induce the  expression  of 
proinflammatory cytokines such as IL-1 and TNF-ot in MHC 
class  II-bearing  APCs  (20,  27).  This  activity  is  a  direct 
function  of two  separate  binding  sites  for  MHC  class  II 
molecules  on  SEA  and  presumably  reflects  the  ability  to 
cross-hnk MHC  class II. Mutation  of either site in SEA or 
papain cleavage of LB3.1 into F(ab) fragments abolishes the 
ability to induce homotypic aggregation. Purified recombi- 
nant SPE-C was tested in the LG-2 homotypic aggregation 
assay and found to be as potent as SEA (Fig.  4) suggesting 
that SPE-C was also capable ofcross-hnking MHC  class II. 
In contrast, neither recombinant SEB nor SPE-A displayed 
any  aggregation  activity  consistent  with  the  presence  of 
only a single MHC class II binding site on these molecules. 
Given that the previous experiments suggested the or-chain 
binding site was absent in SPE-C, two hypotheses were put 
forward to account for the presumed  class  II cross-linking 
activity of SPE-C. The first was that SPE-C binds to MHC 
class II via the zinc-mediated 13-chain site and another uni- 
379  Li et al. Figure  6.  Presence of SPE-C 
dimers in the culture supematant 
of Streptococcus  pyogenes. Concen- 
trated  streptococcal culture su- 
pernatant was run on a nondena- 
turing  SDS  gel  and  blotted to 
nitrocellulose. The Western blot 
was incubated with" an affinity- 
purified rabbit anti-SPE-C anti- 
serum (1:6,000) and detected by 
chemiluminescence. Den, boiled 
in SDS sample buffer; ND, non- 
denatured and reduced. 
Figure  5.  Recombinant SPE-C forms stable dimers in solution. Re- 
combinant SPE-C (5 mg/nfl) was incubated in either 50 mM morpholine 
ethane sulphonic acid/Hepes/acetate buffer, pH 5.0, or 50 mM Tris-Bis- 
Tris buffer, pH 7.0 or 9.0, with either 1 mM EDTA or 10 mM iodoace- 
tamide. One volume of  reducing SDS Laemmli sample buffer was added, 
and then samples were run on a 12.5% SDS gel without boling at a total 
of  0.5 W of  power. 
dentified  site.  The  second  hypothesis  was  that  SPE-C 
might form dimers in solution with  two identical  ~3-chain 
binding sites.  To  test  the  second hypothesis,  recombinant 
SPE-C was examined by nondenaturing SDS-PAGE in an 
attempt  to  observe  SPE-C  oligomers.  Homodimers  were 
clearly visible under both reducing and nonreducing con- 
ditions,  representing  >60% of the total amount of SPE-C 
loaded (Fig. 5). These dimers were absent when the sample 
was  denatured  in  nonreducing  conditions  (not  shown). 
One feature of these dimers was their discrete nature,  even 
in the presence of 1% SDS and  10 mM dithiothreitol.  No 
smearing between dimer and monomer was observed. An- 
other feature  of the  SPE-C  dimers  was  their  dependence 
on neutral or alkaline pH for formation. At conditions be- 
low pH 6.0, virtually no dimers were detected,  whereas at 
pH 7.0,  >60% of the SPE-C was observed in dimer form. 
Neither EDTA nor iodoacetic acid (a sulfhydryl alkylating 
reagent)  affected dimer stability,  indicating  the  absence  of 
covalently disulfide linked homodimers. 
Because the SPE-C used for SDS nondenaturing studies 
was recombinant  material  stored  at high  concentration  (5 
mg/ml), protein dimerization might simply be an artifact of 
high protein concentration and/or recombinant expression 
in E,  coil  Crude  S. pyogenes-derived SPE-C was therefore 
examined by nondenaturing  SDS-PAGE and Western  blot- 
ring using an afffinity-purified anti-SPE-C rabbit anti-serum 
(Fig.  6).  Culture supernatant  from an overnight growth of 
S. pyogenes strain 2035 was first concentrated 1,000-fold by 
ammonium sulfate precipitation because SPE-C was unde- 
tectable in the raw culture  medium.  The concentration of 
wild-type SPE-C was estimated  at  <10  ng/rnl  in  the raw 
S.  pyogenes  culture  supernatant  and  ,'-~10 /~g/ml  in  the 
crude  concentrated  sample.  Electroblotting  of the  SPE-C 
dimer was not as efficient as the monomer,  so the relative 
monomer/dimer  ratios  were  misleading  in  these  experi- 
ments.  Nevertheless,  SPE-C dimer was readily detected in 
the crude  S. pyogenes culture  supernatant  at approximately 
the same proportions as in the recombinant SPE-C, despite 
differences  in  both  purity  and  concentration.  To  analyze 
the effect of pH on SPE-C under more physiological con- 
ditions  (i.e.,  in  the  absence  of SDS),  SPE-C  was dialyzed 
overnight at  either  pH  6.0  or 9.0,  and  then  incubated  at 
varying pHs before separation by size exclusion on a Super- 
ose 12 HPLC column (Fig. 7). The pH 6.0 dialyzed sample 
separated exclusively in the dimer form (95% by peak inte- 
gration),  irrespective  of the  pH  of the  separating  buffer 
(Fig. 7 A). In contrast,  50% of the pH 9.0 dialyzed sample 
dissociated  to the monomer form when  the pH was low- 
ered  to  7.0  or  less  (Fig.  7  B).  The  apparent  molecular 
weight of both the dimer and monomer peaks appeared to 
increase with increasing pH. This manifested in a consistent 
decrease in retention time proportional to increasing pH. 
This was unlikely to be due to decreasing charge interac- 
tions between the protein and Superose column media be- 
cause 0.1 M  NaCI was included as a counter ion to prevent 
such weak ionic interactions.  Thus,  under normal physio- 
logical conditions, the majority of recombinant SPE-C ex- 
isted in dimer form that only dissociated  to the monomer 
in the presence of an ionic detergent or after dialysis at ele- 
vated pH.  This  readily explained  the  apparent  MHC  class 
II cross-linking activity of SPE-C, and moreover, suggested 
that the dimer had two zinc-containing binding sites. 
Discussion 
The  data  presented  in  this  paper  demonstrate  some 
unique  features  of SPE-C  that  set  it  apart  from  all  other 
bacterial SAg. Most notable are (a) the apparent absence of 
the generic MHC  class II oL-chain binding site common to 
every other superantigen  so far studied  and  (b)  the forma- 
tion of stable, noncovalent dimers under normal physiolog- 
ical conditions.  The evidence for the absence of an MHC 
class  II oL-chain binding site in SPE-C is compelling.  First, 
SPE-C  does  not  compete  for SEB  binding  to  the  MHC 
class  II ot chain,  in contrast to SEA, which competes well. 
Second,  amino  acid  comparison  of SPE-C with  SEA and 
SEB  indicate  major differences  in  the  [31-[32 loop  region 
that  forms  the  hydrophobic  ridge  essential  for  a-chain 
binding site. SEB F44.L45.Y46.F47 that is central to MHC 
class  I! or-chain binding is  replaced by T33.T34.H35.T36 
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Figure 7.  1Leversibility  of  SPE-C 
dimer  formation.  Recombinant 
SPE-C (2 mg/ml)  was dialyzed 
overnight in (A) 10 mM BisTris- 
Tris, pH 6.0, or (B) 10 mM Bis- 
Tris-Tris, pH  9.0. Samples (20 
I*l) from each dialysis were incu- 
bated for 1 h at room tempera- 
ture in 100 I~1 50 mM BisTris- 
Tris4).l  M  NaC1 at either pH 
6.0, 7.0, 8.0, or 9.0, and then an- 
alyzed by size exclusion chroma- 
tography.  The  exact retention 
time  of each peak was  deter- 
mined with the Perceptive Bin- 
cad  analysis  software and  is 
shown  beside each peak. Each 
trace  represents  absorbance  at 
280 nm. The resulting figure was 
generated  from  the  Perceptive 
Biocad  program  using  the 
stacked trace mode. The  small 
peak to the right of the pH 6.0 
generated dimer  is  not  mono- 
mer,  but  an  SPE-C  cleavage 
product also seen to the right of 
the pH 9.0 monomer peak. 
in SPE-C. Third, in the crystal structure of SPE-C, the ge- 
netic MHC class II {x-chain binding site is structurally quite 
different from either SEA or SEB. As a consequence, SPE-C 
forms a symmetrical interaction with the same NH2-termi- 
nal region of another SPE-C molecule resulting in a dimer 
with two COOH-terminal domains pointing outwards with 
two potential zinc-containing B-chain binding sites located 
at opposite poles of the  dimer  (23).  Significantly, many of 
the residues in SPE-C that are analogous to oL-chain bind- 
ing residues  in SEA and SEB  (12)  are buried in the dimer 
interface. 
Both recombinant  and wild-type  SPE-C form discrete, 
stable dimers in solution with functional properties consis- 
tent with the dimer observed in the SPE-C crystal structure 
(23). Although we have not formally proven that the solu- 
tion dimer is exactly the same as the crystal dimer, it would 
seem  surprising  that  SPE-C  should  undergo  a  significant 
change from one dimer structure to another during crystal 
formation, given the apparent stability of the solution form. 
Analysis of the dimer by nondenaturing SDS electrophore- 
sis  (in the presence of 1% SDS) revealed a pH dependence 
for dimer formation with a midpoint around pH 6-7 and a 
combination  of both  dimer  and  monomer  forms  above 
neutral pH. Histidine residues might form part of the solu- 
tion dimer interface  (pK of the free imidazole nitrogen is 
6.5) and in the crystal structure, SPE-C H35 and E54 form 
a fourfold zinc coordination with H35 and E54 from a sec- 
ond SPE-C molecule. SPE-C mutants at these positions are 
currently  being  examined  to  confirm  the  importance  of 
dimerization to SPE-C function. The role of zinc in dimer 
formation  is  not  immediately  obvious  from  our  solution 
studies  because  the  addition  of EDTA  had  no  effect  on 
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dimer stability. Notably, the crystal structure dimer was ini- 
tiaUy formed=in the absence of zinc, indicating that it is not 
essential  for dimer  formation.  Zinc  was  only seen  in  this 
position after soaking the crystal in 50 mM zinc (23). Cur- 
rently,  we believe  that the  zinc atom in the  crystal dimer 
interface  is  merely  opportunistic  and  does  not  serve  any 
structural or functional role. Analysis of the solution dimer 
under  more physiological conditions  revealed  that  >95% 
of recombinat SPE-C was in the dimer form and required 
1% SDS or mild alkaline treatment before it dissociated to 
the  monomer.  Evidence  for an alkaline  pH  effect on the 
SPE-C structure was visible by size exclusion chromatogra- 
phy with a proportional decrease in column retention time 
(representing an higher apparent molecular weight) of both 
the dimer and monomer peaks with increasing pH.  It is of 
special note that  the  dimer interface  in the  SPE-C crystal 
structure  is  large  (>900A2),  and  is  formed  from two  re- 
gions, one made up predominantly ofhydrophobic residues 
(the larger in surface area) and a second smaller hydrophilic 
region composed of residues in the 131-]32 loop (23).  One 
possible explanation for the observed features of the SPE-C 
dimer  might  be  that  under  normal  physiological  condi- 
tions,  the  hydrophobic interactions  in the  dimer interface 
predominate,  but are disrupted by ionic detergent  or mild 
alkaline  conditions,  thus  placing a  greater dependence  for 
dimer stability  on the pH-sensitive  hydrophilic regions of 
the interface. 
The zinc-containing B-chain binding site in the SPE-C 
crystal structure consists of residues H167, H201, and D203 
(23).  Although  we  have  not  formally  confirmed by mu- 
tagenesis that these residues form the MHC class II [3-chain 
binding site,  its structural similarity to the zinc site of SEA (8),  the  finding  that  EDTA  destroys  SPE-C  binding  and 
the  strong  cross-competition  between  SEA  and  SPE-C 
suggest that this zinc site coordinates to the MHC class II [3 
chain in a similar manner to SEA  (17-19).  In the  SPE-C 
crystal dimer, two putative [3-chain binding sites are at op- 
posite ends of the dimer in an optimum position to ligate 
two MHC class II molecules (23).  This structure is consis- 
tent with the potent APC activation activity observed, sug- 
gesting that SPE-C cross-hnks two independent MHC class 
II molecules via their [3 chains. 
The ability of SPE-C to prevent TSST binding despite 
the absence of an ~x-chain  binding site in the former toxin 
might best be  explained by steric hindrance  between  the 
two  toxins  across  the  top  of the  MHC  class  II molecule 
rather than direct competition for ct-chain sites.  In support 
of this conclusion,  SPE-C did not inhibit 125I-TSST  bind- 
ing in the presence of EDTA (not shown).  The reciprocal 
competition experiment showed that TSST did not prevent 
SPE-C binding.  One possible explanation for this  might be 
that TSST binding to MHC class II is more restricted than 
SPE-C  due  to  a  greater dependence  on  peptide  residues 
(28).  This question will only be resolved by binding studies 
using a single soluble DR1/peptide combination. 
The zinc-mediated binding site in the COOH-terminal 
domain of SEA, SEE, and SED is a remarkable addition to 
the generic low affinity MHC  class II oL-chain binding of 
other bacterial superantigens that allows these superantigens 
to bind to the MHC class II [3 chain despite the extensive 
polymorphism of this part of the MHC  class II molecule. 
Nevertheless,  SEA  still  requires  additional  binding  to  the 
MHC  class  II cx-chain  site  for  optimal activity.  Multiple 
combined  mutations  in  the  SEA  a-chain  binding  site 
(SEA-F47S.L48A.Y92A)  reduce  T  cell  activity  by  over 
800-fold without significantly altering MHC class II bind- 
ing affinity (19,  20,  29).  The ability of SEA to  cross-link 
MHC class II on the surface of the APC not only increases 
the rate of stability of binding, but also increases the effec- 
tive surface concentration of this superantigen. In addition, 
by also  activating the APC, bivalent superantigens such as 
SEA also promote cell adhesion (seen clearly as homotypic 
aggregation)  and  might  also  activate  costimulations  path- 
ways that further enhance T  cell responses. SPE-C appears 
to achieve the same end but by a different mechanism, dis- 
pensing with the generic or-chain binding site in favor of a 
preformed dimer molecule with two zinc-containing [3-chain 
binding sites.  The trade-off would appear to be a reduced 
TCR  repertoire  because,  like  TSST,  only  human  V[32- 
bearing  T  cells  are  ligated  by SPE-C  (30).  Nevertheless, 
this  does  not  appear  to  affect  the  potency  of SPE-C  in 
vitro, at least towards human T  cells.  One major difference 
between  SPE-C  and  TSST is  that  although  TSST  is  ex- 
tremely potent  towards routine  T  cells, particularly murine 
V[315, SPE-C is completely inactive on murine T  cells de- 
spite  continued  strong binding  to  the  I-E molecule.  The 
simplest  explanation  for  this  is  that  there  are  simply  no 
mouse V[3s ligated by SPE-C. We find this surprising given 
the conservation of function of all other bacterial superanti- 
gens across species and the fact that SPE-C binding to mu- 
fine class II (I-E) is conserved. 
The location of the TCR binding site on SPE-C has not 
been identified.  Given the similarities between SPE-C and 
TSST in both folding and V[3 specificity, it is likely that the 
TCR binding site on SPE-C is located in a similar position 
to TSST along the main COOH-terminal domain o~ helix 
(11,  13, 31) rather than in the shallow groove between the 
COOH-  and NH2-terminal domains as has been mapped 
for SEA,  SEB,  or SEC3.  Analogous residues in SPE-C to 
those  that  form the  murine  V[38.2  TCR  binding  site  of 
SEC3  (32) partially overlap the SPE-C dimer interface and 
would not be available for TCR ligation in the timer mole- 
cule (23). 
Confirmation that the SPE-C dimer is required for opti- 
mal activity at normal toxins concentrations (i.e., in the pi- 
comolar range)  must  await  mutational  analysis,  but  in  its 
absence,  the  functional and biochemical studies presented 
here combined with the recent crystal structure of SPE-C 
propose an intriging model of SPE-C as a preformed dimer 
with two MHC  class II [3-chain binding sites  strategically 
placed  at  opposite poles  to  cross-link MHC  class  II,  and 
potentially two TCR  binding sites  that might also  induce 
cross-hnking of the  TCR.  This study reveals yet another 
potential mechanism of bacterial superantigens  and  high- 
fights the variation that has developed in this family of po- 
tent T  cell mitogens, despite conservation around a similar 
protein fold and continued  targeting of the MHC class II 
molecule as the primary cell surface receptor. 
This work was supported by The Welcome Trust (UK), The Human Frontiers Science Programme, and the 
Health Research Council of New Zealand. J. Fraser is a WeUcome Trust Senior Research Fellow in Medical 
Science. 
Address correspondence to John D. Fraser, Department  of Molecular Medicine,  University of Auckland, 
Private  Bag  92019, Auckland, New  Zealand,  Phone:  64-9-373-7599;  FAX: 64-9-373-7492;  E-mail: 
j d.fraser@auckland.ac.nz 
Received  for publication 14January  1997 and in revised  form  14 April 1997. 
References 
1. Janeway, CJ., J. Yagi, P.J. Conrad, M.E.  Katz, B. Jones,  S.  61-68. 
Vroegop, and S. Buxser. 1989. T-cell responses to Mls and to  2. Marrack,  P.,  and J.  Kappler.  1990. The staphylococcal  en- 
bacterial proteins that mimic its behavior.  Immunol. Rev. 107:  terotoxins  and their relatives. Science (Wash. DC). 248:705- 
382  SPE-C Structure and Function 711. 
3.  Herman,  A., J.W.  Kappler, P.  Marrack,  and A.M.  Pullen. 
1991.  Superantigens: mechanism  of T-cell stimulation and 
role in immune responses. Annu. Rev. Immunol. 9:745-772. 
4.  Fischer, H., M. Dohlsten, M. Lindvall, H.O. Sjogren, and R. 
Carlsson.  1989.  Binding of staphylococcal enterotoxin A  to 
HLA-DR on B cell lines.J. Immunol. 142:3151-3157. 
5.  Fleischer, B., and H. Schrezenmeier. 1988.  T cell stimulation 
by  staphylococcal enterotoxins.  Clonally variable  response 
and requirement for major histocompatibility  complex class II 
molecules  on  accessory or  target  cells. J.  Exp.  Med.  167: 
1697-1707. 
6.  Fraser, J.D. 1989.  High-atllnity binding of staphylococcal en- 
terotoxins A  and B  to  HLA-DR. Nature  (Lond.). 339:221- 
223. 
7.  Mollick, J.A.,  R.G.  Cook,  and R.R.  Rich.  1989.  Class  II 
MHC molecules are specific receptors for staphylococcus en- 
terotoxin A. Science (Wash. DC). 244:817-820. 
8.  Schad, E.M., I. Zaitseva, V.N. Zaitsev, M. Dohlsten, T. Kal- 
land, P.M.  Schlievert, D.H.  Ohlendorf, and L.A. Svensson. 
~1995. Crystal structure of the superantigen staphylococcal en- 
terotoxin type A. EMBO (Eur. Mol. Biol. Organ.)J.  14:3292- 
3301. 
9.  Swaminathan, S., W. Furey, J.  Pletcher, and M.  Sax.  1992. 
Crystal structure of staphylococcal enterotoxin B, a superan- 
tigen. Nature (Lond.). 359:801-806. 
10. Papageorgiou, A.C., K.R. Acharya, R.  Shapiro, E.F. Passa- 
lacqua, R.D. Brehm, and H.S. Tranter.  1995.  Crystal struc- 
ture of the superantigen enterotoxin C2 from staphylococcus 
aureus  reveals a  zinc-binding site.  Structure (Lond.). 3:769- 
779. 
11. Acharya, K.R., E.F. Passalacqua,  E.Y. Jones, K. Harlos, D.I. 
Stuart, R.D. Brehm, and H.S. Tranter. 1994.  Structural basis 
ofsuperantigen action inferred from crystal structure of toxic- 
shock syndrome toxin-1. Nature (Lond.). 367:94-97. 
12. Jardetzky, T.S., J.H. Brown, J.C. Gorga, L.J. Stern, R.G. Ur- 
ban,  Y.I.  Chi,  C.  Stauffacher, J.L.  Strominger,  and  D.C. 
Wiley. 1994. Three-dimensional structure of a human class II 
histocompatibility molecule  complexed  with  superantigen. 
Nature (Lond.). 368:711-718. 
13. Kim, J.,  R.  Urban, J.  L.  Strominger, and D.  Wiley.  1994. 
Toxic shock syndrome toxin-1 complexed with a major his- 
tocompatibility molecule  HLA-DR1.  Science (Wash.  DC). 
266:1870-1874. 
14. Seth, A., L.J.  Stern, T.H.  Ottenhoff,  I. Engel, M.J.  Owen, 
J.R.  Lamb,  R.D.  Klausner,  and D.C.  Wiley.  1994.  Binary 
and  ternary  complexes  between  T-cell  receptor,  class  II 
MHC  and  superantigen in  vitro.  Nature  (Lond.). 369:324-- 
327. 
15. Wen, R., M.A. Blackman, and D.L. Woodland. 1995.  Vari- 
able influence of MHC polymorphism on the recognition of 
bacterial  superantigens  by  T  cells. J.  lmmunol.  155:1884- 
1892. 
16. Wen, R., G.A. Cole, S. Surman, M.A. Blackman, and D.L. 
Woodland. 1996.  Major histocompatibility complex class lI- 
associated peptides control the presentation of bacterial super- 
antigens to T cells.J. Exp. Med.  183:1083-1092. 
17. Hudson,  K.R., R.E.  Tiedemann, R.G.  Urban,  S.C.  Lowe, 
J.L.  Strominger,  and J.D.  Fraser.  1995.  Staphylococcal en- 
terotoxin A has two cooperative binding sites on major histo- 
compatibility complex class II.J. Exp. Med. 182:711-720. 
18. Abrahmsen, L., M. Dohlsten, S. Segren, P. Bjork, E. Jonsson, 
and T. Kalland. 1995.  Characterization of two distinct MHC 
class II binding sites  in the superantigen staphylococcal en- 
terotoxin A. EMBO (Eur. Mol. Biol. Organ.)  J. 14:2978-2986. 
19. Kozono, H., D. Parker, J. White, P. Marrack, andJ. Kappler. 
1995.  Multiple binding sites  for bacterial superantigens on 
soluble class II MHC molecules. Immunity. 3:187-196. 
20. Tiedemann,  R.E.,  and J.D.  Fraser.  1996.  Cross-linking of 
major histocompatibility complex class II by staphylococcal 
enterotoxin A is required for superantigen activity. J.  Immu- 
nol. 157:3958-3966. 
21. Wannamaker, L.W., and P.M. Schlievert. 1988. Exotoxins of 
group A Streptococci. In Bacterial Toxins. Vol. 4. C.M. Harde- 
gree and A.T. Tu, editors. Marcel Dekker, New York. 267- 
295. 
22. Mollick, J.A.,  G.G.  Miller, J.M.  Musser,  R.G.  Cook,  D. 
Grossman, and R.R.  Rich.  1993.  A novel superantigen iso- 
lated from pathogenic strains  of Streptococcus pyogenes with 
amino terminal homology to staphylococcal enterotoxins B 
and C.J.  Clin. Invest. 92:710-719. 
23. Roussel, A., H.M. Baker, J.D. Fraser, and E.N. Baker. 1996. 
Crystal structure  of the  streptococcal superantigen  SPE-C: 
dimerisation and zinc binding suggests a novel mode of inter- 
action with  MHC  class  II  molecules.  Nat.  Struct. Biol. In 
press. 
24. Hudson, K.R., H. Robinson, andJ.D. Fraser. 1993. Two ad- 
jacent residues in staphylococcal enterotoxins A and E deter- 
mine T  cell receptor V  beta specificity. J.  Exp.  Med.  177: 
175-184. 
25. Chomezynski, P., and N.  Sacchi.  1987.  Single-step method 
of RNA isolation by acid guanidinium thiocynate-phenol- 
chloroform extraction. Anal.  Biochem. 162:156-163. 
26. Vallee, B.L., and D.S. Auld. 1990.  Zinc coordination, func- 
tion, and structure of zinc enzymes and other proteins. Bio- 
chemistry. 29:5641-5659. 
27. Mehindate, K., J. Thibodeau, M. Dohlsten, T. Kalland, R.P. 
Sekaly, and W. Mourad. 1995.  Cross-linking of major histo- 
compatibility complex class II molecules by  staphylococcal 
enterotoxin A superantigen is a requirement for inflammatory 
cytokine gene expression.J. Exp. Med. 182:1573-1577. 
28. Thibodeau, J.,  I.  Cloutier, P.M.  Lavoie, N. Labrecque, W. 
Mourad,  T. Jardetzky,  and  R.P.  Sekaly.  1994.  Subsets  of 
HLA-DR1 molecules defined by SEB and TSST-1 binding. 
Science (Wash. DC). 266:1874-1878. 
29. Tiedemann, R.E.,  R.J.  Urban,  Strominger, and J.D.  Fraser. 
1995.  Isolation  of  HLA-DRl.(staphylococcal  enterotoxin 
A)2  trimers  in  solution.  Proc. Natl.  Acad. Sci.  USA.  92: 
12156-12159. 
30. Choi, Y., J.W. Kappler, and P. Marrack. 1991.  A superanti- 
gen encoded in the open reading frame of the 3' long termi- 
nal repeat of mouse mammary tumour virus. Nature (Lond.). 
350:203-207. 
31. Hurley, J.M.,  R.  Shimonkevitz, A. Hanagan,  K. Enney, E. 
Boen, S. Malmstrom, B.L. Kotzin, and M. Matsumura. 1995. 
Identification of class  II  major  histocompatibility complex 
and T  cell receptor binding sites  in the superantigen toxic 
shock syndrome toxin 1.J. Exp. Med. 181:2229-2235. 
32. Fields, B.A., E.L.  Malchiodi, H.  Li, X. Ysern,  C.V.  Stauf- 
facher, P.M. Schlievert, K. Karjalainen, and R.A. Marriuzza. 
1996.  Crystal structure  of a  T  cell receptor J3-chain  com- 
plexed with  a  superantigen.  Science (Wash.  DC).  384:188- 
192. 
383  Li et al. 